bearish
SK Bioscience (302440 KS): Murky Outlook On Weak Vaccine Demand And Flooding Supply
238 Views06 Sep 2022 23:15
SUMMARY
- SK Bioscience (302440 KS) received approval for Korea’s first locally-developed COVID-19 vaccine, SKYCovione. The company is seeking European approval and plans to apply for emergency use listing to the WHO.
- The company is a late entrant in the overcrowded domestic vaccine market. Currently, six vaccines are approved for use in South Korea. Moreover, demand outlook is uncertain beyond 2022.
- Recently, the company has dropped a multinational phase 3 trial of P2-VP8, trivalent rotavirus vaccine. Among the non-COVID pipeline, P2-VP8 was in the most advanced stage of clinical trial.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SK Bioscience (302440 KS): Flu Vaccine Output Resumes; Next-Gen Typhoid Vaccine Is On Card14 Sep 2023
- SK Bioscience (302440 KS): Core Vaccines Gaining Traction; COVID Vaccine Gets International Approval13 Jun 2023
- SK Bioscience (302440 KS): Disappointing 2022 Result; Non-COVID Vaccines Are Key to Revival05 Mar 2023
- SK Bioscience (302440 KS): Murky Outlook On Weak Vaccine Demand And Flooding Supply06 Sep 2022
- SK Chemical's CEO Sells All His Shares of SK Bioscience22 Apr 2022
- Metrica Partners Urges SK Chemicals to Partially Sell SK Bioscience & Pay Higher Dividends08 Sep 2021
x